{
    "id": "dbpedia_6494_2",
    "rank": 36,
    "data": {
        "url": "https://parkinsonsnewstoday.com/author/yedida/page/2/",
        "read_more_link": "",
        "language": "en",
        "title": "Yedida Y Bogachkov PhD, Author at Parkinson's News Today",
        "top_image": "https://secure.gravatar.com/avatar/ad8d4f029490faf917df711120b025c1.jpg?d=mp&s=1200",
        "meta_img": "https://secure.gravatar.com/avatar/ad8d4f029490faf917df711120b025c1.jpg?d=mp&s=1200",
        "images": [
            "https://insight.bionewsservices.com/matomo.php?idsite=16&rec=1",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2022/09/PARnewstoday.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-fb.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-ig.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-sc.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-youtube.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2023/08/color-pin.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-fb.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-ig.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-sc.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-youtube.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2023/08/color-pin.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/09/Head-Shot-8.20.21-96x96.jpg",
            "https://bionews.com/global-code/images/linkedin.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/06/BionewsLogo_Black.svg",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-fb.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2024/07/x-blue-logo-56.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-ig.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-sc.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2021/06/color-youtube.png",
            "https://parkinsonsnewstoday.com/wp-content/uploads/2023/08/color-pin.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Yedida Y Bogachkov PhD"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her...",
        "meta_lang": "en",
        "meta_favicon": "https://parkinsonsnewstoday.com/wp-content/uploads/2024/06/cropped-BioNews_Favicon-32x32.png",
        "meta_site_name": "Parkinson's News Today",
        "canonical_link": "https://parkinsonsnewstoday.com/author/yedida/page/2/",
        "text": "Phase 2b Trial of Pirepemat, to Prevent Falls, Approved in Sweden\n\nIRLAB has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2b trial for its investigational medication, pirepemat (previously known as IRL752), which is intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. “Pirepemat has potential to be the first…\n\nParkinson’s UK Funds Work Into Inflammation That May Drive Disease\n\nParkinson’s UK is investing up to £3 million (about $3.96 million) over the next two-and-a-half years to support research into inflammation that could help in developing therapies to slow the progression of Parkinson’s disease. The funding will come through the organization’s Virtual Biotech program — the therapy development…\n\nApomorphine Infusion Device Again Before FDA for Approval\n\nSupernus Pharmaceuticals has again applied to the U.S. Food and Drug Administration (FDA) requesting that its apomorphine infusion device (SPN-830), allowing continuous treatment of Parkinson’s disease motor symptoms, be approved. “SPN-830 is an important product candidate which, if approved by the FDA, represents a novel approach for PD…\n\nStudy: Parkinson’s Patients Speak 60% Less Than Healthy Peers\n\nPeople with Parkinson’s disease verbally communicate less than those without the neurodegenerative disorder, according to a recent study that discovered that patients speak about 60% less than their healthy peers. Apart from the tremors and movement issues associated with Parkinson’s, the disease also can disrupt aspects of a…\n\nUCB and Novartis Join to Advance Oral Therapy Now in Phase 2 Trial\n\nUCB is partnering with Novartis to co-develop and potentially market UCB0599, a small molecule to inhibit misfolding of the alpha-synuclein protein now in a Phase 2 clinical trial enrolling people with Parkinson’s disease. The agreement also includes an option to co-develop UCB7853 — an antibody against alpha-synuclein —…\n\nSwedish Researchers Develop Tools to Manage Care More Effectively\n\nA Swedish group of doctors and researchers are working to develop new tools and models to more effectively manage and treat patients with Parkinson’s disease. The group, led by Per Odin, MD, PhD, professor at Lund Universit’s strategic research area Multipark and senior attending physician at Skåne University Hospital,…\n\nWearable, AI-assisted UltiGesture May Curb Gait Freezing\n\nAn interdisciplinary research team from William and Mary University and Virginia Commonwealth University (VCU) are working on artificial intelligence programming to help develop a wearable device to treat freezing of gait (FoG), the temporary inability to move while walking, which is a motor symptom of Parkinson’s disease. “Freezing of…\n\nParkinson’s Foundation Opens 2022 Community Grant Applications\n\nApplications are open for the Parkinson’s Foundation 2022 community grant cycle, with $1 million to be awarded to help fund community-based health, wellness, and education programs supporting those affected by Parkinson’s disease. Since 1957, the Foundation has invested more than $400 million toward Parkinson’s research and clinical care.\n\nGut Microbiome of Patients Found to Contain Unique Bacterial Profile\n\nResearchers at the biotech company Second Genome have identified specific intestinal bacterial strains that are either enriched or depleted in patients with Parkinson’s disease, according to a press release. The data were presented in a poster, titled “Strain-Level Meta-Analysis of Parkinson’s Disease-Associated Gut Microbiome,” at…"
    }
}